Sex and gender influences on pharmacological response: An overview

Expert Review of Clinical Pharmacology

Volumn 7, Issue 4, 2014, Pages 469-485

  Franconi, Flavia ^a,b   Campesi, Ilaria ^a,b  

^a UNIVERSITY OF SASSARI   (Italy)

^b Laboratory of Sex Gender Medicine   (Italy)

Author keywords

adherence; antidiabetic drugs; drug adverse effect; gender; medication; sex

Indexed keywords

ALPRAZOLAM; ANTIDIABETIC AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL PEPTIDASE IV; ERYTHROMYCIN; FLUOROURACIL; IBUPROFEN; INSULIN DERIVATIVE; METFORMIN; PLACEBO; RANITIDINE; TAMOXIFEN; VILDAGLIPTIN; ZOLPIDEM; DRUG;

AREA UNDER THE CURVE; AWARENESS; BIOEQUIVALENCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; ENVIRONMENTAL FACTOR; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLACEBO EFFECT; PRESCRIPTION; REVIEW; SEX DIFFERENCE; SOCIAL DETERMINANTS OF HEALTH; SOCIAL STATUS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANIMAL; PHARMACOLOGY; SAFETY; SEXUAL DEVELOPMENT;

ANIMALS; HUMANS; MEDICATION ADHERENCE; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; PLACEBO EFFECT; SAFETY; SEX CHARACTERISTICS;

EID: 84903194379     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.922866     Document Type: Review

References (296)

1. Stoller R. Sex and gender : On the development of masculinity and femininity. Science House New York; NY, USA: 1986
2. WHO. Women and health: Today's evidence tomorrow's agenda. Gender, Women and Health WHO; Geneva, Switzerland: 2009
3. Legato MJ. The homosexual and transgendered individual: Deviant or part of the normal human continuum?. Gend Med 2011;8(4):280-2
4. Grumbach MM, Hughes IA, Conte FA. Disorders of sex differentiation. In: Larsen PR, Kronenberg HM, Melmed S, editors. Williams textbook of endocrinology. WB Saunders; Philadelphia, PA, USA: 2003. p. 842-1002
5. Jimenez-Chillaron JC, Isganaitis E, Charalambous M, et al. Intergenerational transmission of glucose intolerance and obesity by in utero undernutrition in mice. Diabetes 2009;58(2):460-8
6. Nugent BM, McCarthy MM. Epigenetic underpinnings of developmental sex differences in the brain. Neuroendocrinology 2011;93(3):150-8
7. Collins JL, Lehnherr J, Posner SF, Toomey KE. Ties that bind: Maternal and child health and chronic disease prevention at the Centers for Disease Control and Prevention. Prev Chronic Dis 2009;6(1): A01
8. Regitz-Zagrosek V. Sex and gender differences in pharmacology. In: Ganten D, Page CP, Rosenthal W, Michel MC, Barrett JE, Geppetti P, editors. Handbook of experimental pharmacology. Volume 214 Springer; 2012
9. Rubin G. The traffic in women: Notes on the 'Political Economy' of sex. In: Reiter R, editor. Toward an anthropology of women. Monthly Review Press; NY, USA: 1975
10. Fausto-Sterling A. The Bare Bones of Sex: Part 1- Sex and Gender. In: Harding, S. "Signs: Journal of Women in Culture and Society". The University of Chicago Press; Chicago; 2005;1491-527
11. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human Disease. Clin Exp Nephrol 2005;9(3):195-205 (Pubitemid 41414118
12. Geller SE, Adams MG, Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. J Womens Health (Larchmt) 2006;15(10): 1123-31 (Pubitemid 46157484
13. Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: Have we made progress?. J Womens Health (Larchmt) 2011;20(3):315-20
14. Wizemann T, Pardue M. Exploring the biological contributions to human health: Does sex matter?. National Academy Press; Washington, USA: 2001
15. Marino M, Masella R, Bulzomi P, et al. Nutrition and human health from a sex-gender perspective. Mol Aspects Med 2011;32(1):1-70
16. Kuehn BM. FDA warning: Driving may be impaired the morning following sleeping pill use. JAMA 2013;309(7):645-6
17. Legato MJ. Principles of Gender-Specific Medicine. Elsevier Academic Press; Amsterdam; Boston: 2009. p. 704
18. Maselli A, Matarrese P, Straface E, et al. Cell sex: A new look at cell fate studies. Faseb J 2009;23(4):978-84
19. Oertelt-Prigione S, Regitz-Zagrosek V. Sex and gender aspects in clinical medicine. Springer and Verlag; London, UK: 2012
20. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in Drug responses. Pharmacol Res 2007;55(2):81-95
21. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: Interaction with biological differences between men and women. Br J Pharmacol 2014;171(3):580-94
22. Franconi F, Carru C, Malorni W, et al. The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des 2011; 17(11):1095-107
23. Franconi F, Carru C, Spoletini I, et al. A GENS-based approach to cardiovascular pharmacology: Impact on metabolism, pharmacokinetics and pharmacodynamics. Ther Deliv 2011;2(11):1437-53
24. Doyal L. What makes women sick: Gender and the political economy of health. Macmillan; London, UK: 1995
25. Ross CE, Bird CE. Sex stratification and health lifestyle: Consequences for men's and women's perceived health. J Health Soc Behav 1994;35(2):161-78
26. Bird CE, Fremont AM. Gender, time use, and health. J Health Soc Behav 1991;32(2): 114-29
27. Krantz DS, Schaeffer MA, Davia JE, et al. Extent of coronary atherosclerosis, type A behavior, and cardiovascular response to social interaction. Psychophysiology 1981; 18(6):654-64 (Pubitemid 12239658
28. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23(3): 809-13 (Pubitemid 24074965
29. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001;104(17):2024-8 (Pubitemid 33027041
30. Elovainio M, Ferrie JE, Singh-Manoux A, et al. Socioeconomic differences in cardiometabolic factors: Social causation or health-related selection?. Evidence from the Whitehall II Cohort Study, 1991-2004. Am J Epidemiol 2011;174(7):779-89
31. Ghiadoni L, Donald AE, Cropley M, et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000; 102(20):2473-8
32. Veronesi G, Ferrario MM, Chambless LE, et al. Gender differences in the association between education and the incidence of cardiovascular events in Northern Italy. Eur J Public Health 2010;21(6):762-7
33. Giskes K, Kunst AE, Benach J, et al. Trends in smoking behaviour between 1985 and 2000 in nine European countries by education. J Epidemiol Community Health 2005;59(5):395-401
34. Kulik MC, Menvielle G, Eikemo TA, et al. Educational inequalities in three smoking-related causes of death in 18 European populations. Nicotine Tob Res 2014;16(5):507-18
35. Bjarnason NH. Drug metabolism and variability. N Engl J Med 2005;353(9): 955-6.author reply 955-956
36. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36(6):425-38
37. Dobrinas M, Cornuz J, Oneda B, et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011;90(1):117-25
38. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007;64(18): 1917-21 (Pubitemid 47462906
39. Anderson GD. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin Pharmacokinet 2005;44(10): 989-1008 (Pubitemid 41356388
40. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44: 499-523 (Pubitemid 38263851
41. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48(3):143-57
42. Marazziti D, Baroni S, Picchetti M, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: Effect of sex. CNS Spectr 2013;1-10
43. Wang TY, Angiolillo DJ, Cushman M, et al. Platelet biology and response to antiplatelet therapy in women: Implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol 2012;59(10):891-900
44. Budesa T, Egnor E, Howell L. Gender influence on perceptions of healthy and unhealthy lifestyles (all volumes (2001-2008). Paper 3 2008
45. Glaser R, Sheridan J, Malarkey WB, et al. Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. Psychosom Med 2000;62(6):804-7 (Pubitemid 32009087
46. Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. Ann Med 2006;38(8):530-44 (Pubitemid 46292018
47. Campesi I, Carru C, Zinellu A, et al. Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. Am J Transl Res 2013;In press
48. Franconi F, Campesi I, Occhioni S, Tonolo G. Sex-gender differences in Diabetes vascular complications and treatment. Endocr Metab Immune Disord Drug Targets 2012;12(2):179-96
49. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: Evolving knowledge. J Am Coll Cardiol 2009;54(17): 1561-75
50. Hawker GA, Wright JG, Coyte PC, et al. Differences between men and women in the rate of use of hip and knee arthroplasty. N Engl J Med 2000;342(14):1016-22 (Pubitemid 30180649
51. Juni P, Low N, Reichenbach S, et al. Gender inequity in the provision of care for hip disease: Population-based cross-sectional study. Osteoarthritis Cartilage 2010;18(5): 640-5
52. Holtzman J, Saleh K, Kane R. Gender differences in functional status and pain in a Medicare population undergoing elective total hip arthroplasty. Med Care 2002; 40(6):461-70
53. Katz JN, Wright EA, Guadagnoli E, et al. Differences between men and women undergoing major orthopedic surgery for degenerative arthritis. Arthritis Rheum 1994;37(5):687-94 (Pubitemid 24145072
54. Mark DB, Shaw LK, DeLong ER, et al. Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med 1994;330(16):1101-6 (Pubitemid 24118266
55. Raine RA, Black NA, Bowker TJ, Wood DA. Gender differences in the management and outcome of patients with acute coronary artery disease. J Epidemiol Community Health 2002;56(10):791-7
56. Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 2000;343(1):8-15 (Pubitemid 30447986
57. Harrold LR, Lessard D, Yarzebski J, et al. Age and sex differences in the treatment of patients with initial acute myocardial infarction: A community-wide perspective. Cardiology 2003;99(1):39-46 (Pubitemid 36206634
58. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: A report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158(9): 981-8 (Pubitemid 28213575
59. Petticrew M, McKee M, Jones J. Coronary artery surgery: Are women Discriminated against?. BMJ 1993;306(6886):1164-6
60. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention Drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008;14(3):271-80 (Pubitemid 351711978
61. El-Menyar A, Zubaid M, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol 2009;104(8): 1018-22
62. Halvorsen S, Eritsland J, Abdelnoor M, et al Gender differences in management and outcome of acute myocardial infarctions treated in 2006-2007. Cardiology 2009; 114(2):83-8
63. Aguilar MD, Lazaro P, Fitch K, Luengo S. Gender differences in clinical status at time of coronary revascularisation in Spain. J Epidemiol Community Health 2002;56(7): 555-9 (Pubitemid 34712955
64. van Miltenburg-van Zijl AJ, Simoons ML, Bossuyt PM, et al. Variation in the use of coronary angiography in patients with unstable angina is related to differences in patient population and availability of angiography facilities, without affecting prognosis. Eur Heart J 1996;17(12): 1828-35
65. Haglund B, Koster M, Nilsson T, Rosen M . Inequality in access to coronary revascularization in Sweden. Scand Cardiovasc J 2004;38(6):334-9 (Pubitemid 40123790
66. Nante N, Messina G, Cecchini M, et al. Sex differences in use of interventional cardiology persist after risk adjustment. J Epidemiol Community Health 2009;63(3): 203-8
67. Agency for Healthcare Research and Quality. National healthcare disparities report. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality; Rockville, MD, USA: 2004
68. Agency for Healthcare Research and Quality. Cancer care quality measures: Diagnosis and treatment of colorectal cancer U.S. Department of Health and Human Services; Rockville, MD, USA: 2006
69. Agency for Healthcare Research and Quality. National healthcare disparities report. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality; Rockville, MD, USA: 2006
70. Bryce CL, Angus DC, Arnold RM, et al. Sociodemographic differences in early access to liver transplantation services. Am J Transplant 2009;9(9):2092-101
71. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005;165(11):1267-73 (Pubitemid 40989591
72. Wexler DJ, Grant RW, Meigs JB, et al. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28(3):514-20 (Pubitemid 40315306
73. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF). Intensive Care Med 2011;37(4):619-26
74. Ernst E. Placebo: New insights into an old enigma. Drug Discov Today 2007; 12(9-10)):413-18 (Pubitemid 46636376
75. Howland RH. Understanding the placebo effect. Part 1: Placebo use in clinical trials. J Psychosoc Nurs Ment Health Serv 2008; 46(5):17-20
76. Stewart-Williams S, Podd J. The placebo effect: Dissolving the expectancy versus conditioning debate. Psychol Bull 2004; 130(2):324-40 (Pubitemid 38317814
77. Franconi F, Campesi I, Occhioni S, et al. Sex and gender in adverse drug events, addiction, and placebo. Handb Exp Pharmacol 2012(214):107-26
78. Aslaksen PM, Bystad M, Vambheim SM, Flaten MA. Gender differences in placebo analgesia: Event-related potentials and emotional modulation. Psychosom Med 2011;73(2):193-9
79. Frank E, Thase ME, Spanier CA, et al. Gender-specific response to depression treatment. J Gend Specif Med 1999;2(4): 40-4
80. Jensen MP, Karoly P. Motivation and expectancy factors in symptom perception: A laboratory study of the placebo effect. Psychosom Med 1991;53(2):144-52
81. Flaten MA, Aslaksen PM, Finset A, et al. Cognitive and emotional factors in placebo analgesia. J Psychosom Res 2006;61(1):81-9 (Pubitemid 43927853
82. Paulson PE, Minoshima S, Morrow TJ, Casey KL. Gender differences in pain perception and patterns of cerebral activation During noxious heat stimulation in humans. Pain 1998;76(1-2):223-9
83. Johansen O, Brox J, Flaten MA. Placebo and Nocebo responses, cortisol, and circulating beta-endorphin. Psychosom Med 2003;65(5):786-90 (Pubitemid 37163384
84. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: Recent advances and current thought. Annu Rev Psychol 2008;59:565-90
85. Donner NC, Lowry CA. Sex differences in anxiety and emotional behavior. Pflugers Arch 2013;465(5):601-26
86. Flaten MA, Aslaksen PM, Lyby PS, Bjorkedal E. The relation of emotions to placebo responses. Philos Trans R Soc Lond B Biol Sci 2011;366(1572):1818-27
87. Boucher BA, Hanes SD. Pharmacokinetic alterations after severe head injury. Clinical relevance. Clin Pharmacokinet 1998;35(3): 209-21 (Pubitemid 28430035
88. Rump AF, Siekmann U, Kalff G. Effects of hyperbaric and hyperoxic conditions on the disposition of drugs: Theoretical considerations and a review of the literature. Gen Pharmacol 1999;32(1):127-33 (Pubitemid 28540801
89. Peng HT, Cheung B. A review of psychophysiological stressors on pharmacokinetics. J Clin Pharmacol 2011; 51(11):1499-518
90. Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol 1999;47(4): 391-6 (Pubitemid 29161271
91. Xu J, Mercury J, Zhang Z, Xu F. Psychological, social and behavioural factors that influence drug efficacy: A noteworthy research subject in clinical pharmacology. Br J Clin Pharmacol 2008;66(6):901-2
92. Duan JJ, Zhou T, Chen X, et al. Pharmacokinetics of 5-fluorouracil and cyclophosphamide in Depression rats. Eur Rev Med Pharmacol Sci 2012;16(4):427-36
93. Konstandi M. Psychophysiological stress: A significant parameter in Drug pharmacokinetics. Expert Opin Drug Metab Toxicol 2013;9(10):1317-34
94. Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clin Proc 2011;86(4):304-14
95. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19(4): 357-62 (Pubitemid 38916494
96. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2000;9(10):1169-75 (Pubitemid 32014716
97. Murray MD, Young JM, Morrow DG, et al. Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. Am J Geriatr Pharmacother 2004;2(1):53-65 (Pubitemid 38559459
98. Ostrowski M. Report takes aim at America's other drug problem: Poor adherence. J Fam Pract 2007;56:734
99. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr 2009;52(2):290-3
100. Sabaté E. Adherence to long-Term therapies: Evidence for action. WHO; Geneva, Switzerland: 2003
101. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA 2006; 296(21):2563-71 (Pubitemid 44903860
102. Huth EJ, Murray TJ. Medicine in quotations: Views of health and disease through the ages. American College of Physicians; Philadelphia, PA, USA: 2006
103. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood) 2011; 30(1):91-9
104. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010;48(3): 196-202
105. Hankivsky O. Women's health, men's health, and gender and health: Implications of intersectionality. Soc Sci Med 2012; 74(11):1712-20
106. Verbrugge LM. Gender and health: An update on hypotheses and evidence. J Health Soc Behav 1985;26(3):156-82
107. Courtenay WH. Constructions of masculinity and their influence on men's well-being: A theory of gender and health. Soc Sci Med 2000;50(10):1385-401 (Pubitemid 30100386
108. Thunander Sundbom L, Bingefors K. Women and men report different behaviours in, and reasons for medication non-Adherence: A nationwide Swedish survey. Pharm Pract (Granada) 2012;10(4): 207-21
109. Pound P, Britten N, Morgan M, et al. Resisting medicines: A synthesis of qualitative studies of medicine taking. Soc Sci Med 2005;61(1):133-55 (Pubitemid 40545066
110. Isacson D, Bingefors K. Attitudes towards drugs-A survey in the general population. Pharm World Sci 2002;24(3):104-10 (Pubitemid 34754764
111. Horne R, Graupner L, Frost S, et al. Medicine in a multi-cultural society: The effect of cultural background on beliefs about medications. Soc Sci Med 2004; 59(6):1307-13 (Pubitemid 38759888
112. Petty RE, Wegener DT, Fabrigar LR. Attitudes and attitude change. Annu Rev Psychol 1997;48;609-47 (Pubitemid 127485188
113. Phatak HM, Thomas J 3rd. Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann Pharmacother 2006; 40(10):1737-42 (Pubitemid 44544869
114. Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 2007;69(1-3):158-64 (Pubitemid 350051686
115. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: Three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26(5): 331-42 (Pubitemid 32989555
116. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19(11):1190-6 (Pubitemid 44633590
117. Donovan JL, Blake DR. Patient noncompliance: Deviance or reasoned decisionmaking?. Soc Sci Med 1992;34(5):507-13
118. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 2: The influence of gender and type of impairment. J Clin Psychiatry 2001;62(Suppl 22):34-7
119. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: Influence of patient-physician communication. JAMA 2002;288(11):1403-9 (Pubitemid 35025915
120. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17(9):2659-69 (Pubitemid 29415221
121. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005;59(1):97-102 (Pubitemid 41399883
122. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19(2):322-8 (Pubitemid 32112842
123. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28(27):4120-8
124. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila) 2011;4(9):1360-5
125. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: What a difference a decade makes. Circulation 2011;124(19): 2145-54
126. Lewey J, Shrank WH, Bowry AD, et al. Gender and racial disparities in adherence to statin therapy: A meta-Analysis. Am Heart J 2013;165(5):665-78.678 e661
127. Bierman AS. Sex matters: Gender disparities in quality and outcomes of care. Cmaj 2007;177(12):1520-1 (Pubitemid 350248164
128. Cherry N, Shalansky K. Efficacy of intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Health Syst Pharm 2002;59(18):1736-41 (Pubitemid 35033911
129. Mosca L, Mochari-Greenberger H, Dolor RJ, et al. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010;3(2):120-7
130. Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient characteristics associated with medication adherence. Clin Med Res 2013; 11(2):54-65
131. Manteuffel M, Williams S, Chen W, et al. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2013;23(2):112-19
132. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002;40(9):1589-95 (Pubitemid 35253636
133. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117(8):1028-36
134. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008;156(6): 1045-55
135. Tuppin P, Neumann A, Danchin N, et al. Combined secondary prevention after hospitalization for myocardial infarction in France: Analysis from a large administrative database. Arch Cardiovasc Dis 2009;102(4): 279-92
136. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A guideline from the American Heart Association. Circulation 2011;123(11):1243-62
137. Kirchmayer U, Agabiti N, Belleudi V, et al. Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: A population-based cohort study in Rome, Italy. J Clin Pharm Ther 2012;37(1):37-44
138. Kumbhani DJ, Fonarow GC, Cannon CP, et al. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med 2013; 126(1):74 e71-79
139. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120(16): 1598-605
140. Holt E, Joyce C, Dornelles A, et al. Sex differences in barriers to antihypertensive medication adherence: Findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc 2013; 61(4):558-64
141. Granger BB, Ekman I, Granger CB, et al. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail 2009;11(11):1092-8
142. Kautzky-Willer A, Stich K, Hintersteiner J, et al. Sex-specific- differences in cardiometabolic risk in type 1 diabetes: A cross-sectional study. Cardiovasc Diabetol 2013;12:78
143. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(2):117-25
144. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. Aids 2000;14(2):151-5 (Pubitemid 30116440
145. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication Diaries. AIDS Patient Care STDS 2002; 16(12):599-608 (Pubitemid 36008059
146. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med 2003;10(1): 1-14 (Pubitemid 36378135
147. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999;13(3):185-97 (Pubitemid 29155987
148. Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: The impact of social instability. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S149-53
149. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17(10): 756-65 (Pubitemid 35286241
150. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):21-30 (Pubitemid 30432540
151. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17(5):377-81 (Pubitemid 34626108
152. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003;18(4):248-57 (Pubitemid 36529041
153. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28(1):47-58 (Pubitemid 33104527
154. Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: Physician experience and enhanced adherence to prescription refill. Antivir Ther 2003;8(5): 471-8 (Pubitemid 37351566
155. Berg KM, Demas PA, Howard AA, et al. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004;19(11):1111-17 (Pubitemid 39552581
156. Horne R. Compliance, adherence, and concordance: Implications for asthma treatment. Chest 2006;130(1 Suppl): 65S-72S
157. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: An unrecognized cardiovascular risk factor. MedGenMed 2007;9(3):58
158. Domenighetti G, Luraschi P, Marazzi A. Hysterectomy and sex of the gynecologist. N Engl J Med 1985;313(23):1482 (Pubitemid 16212341
159. Lagro-Janssen AL. [Medicine is not genderneutral: Influence of physician sex on medical care]. Ned Tijdschr Geneeskd 2008;152(20):1141-5
160. Enriquez JR, Pratap P, Zbilut JP, et al. Women tolerate drug therapy for coronary artery disease as well as men Do, but are treated less frequently with aspirin, beta-blockers, or statins. Gend Med 2008; 5(1):53-61 (Pubitemid 351506546
161. Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ 1993;307(6908): 846-8 (Pubitemid 23281752
162. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART nonadherence: A literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011;8(4):277-87
163. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: Results of the ISSEO survey. Inflamm Bowel Dis 2011;17(6):1270-6
164. Hawthorne AB, Rubin G, Ghosh S. Review article: Medication non-Adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008;27(12):1157-66 (Pubitemid 351697281
165. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 2004;42(3):200-9
166. Lurie N, Slater J, McGovern P, et al. Preventive care for women. Does the sex of the physician matter?. N Engl J Med 1993; 329(7):478-82
167. Bertakis KD, Helms LJ, Callahan EJ, et al. The influence of gender on physician practice style. Med Care 1995;33(4):407-16
168. Levy S, Dowling P, Boult L, et al. The effect of physician and patient gender on preventive medicine practices in patients older than fifty. Fam Med 1992;24(1): 58-61
169. Franks P, Clancy CM. Physician gender bias in clinical decision making: Screening for cancer in primary care. Med Care 1993; 31(3):213-18
170. Roter D, Lipkin M Jr, Korsgaard A. Sex differences in patients' and physicians' communication During primary care medical visits. Med Care 1991;29(11):1083-93
171. Roter DL, Hall JA. Why physician gender matters in shaping the physician-patient relationship. J Womens Health 1998;7(9): 1093-7
172. Sandhu H, Adams A, Singleton L, et al. The impact of gender dyads on Doctor-patient communication: A systematic review. Patient Educ Couns 2009;76(3): 348-55
173. Schmittdiel J, Grumbach K, Selby JV, Quesenberry CP Jr. Effect of physician and patient gender concordance on patient satisfaction and preventive care practices. J Gen Intern Med 2000;15(11):761-9
174. Kallai I, Barke A, Voss U. The effects of experimenter characteristics on pain reports in women and men. Pain 2004;112(1-2): 142-7 (Pubitemid 39371029
175. Aslaksen PM, Myrbakk IN, Hoifodt RS, Flaten MA. The effect of experimenter gender on autonomic and subjective responses to pain stimuli. Pain 2007;129(3): 260-8 (Pubitemid 46754566
176. Hadjistavropoulos T, McMurtry B, Craig KD. Beautiful faces in pain: Biases and accuracy in the perception of pain. Psychology and Health 1996;11: 411-20
177. Weisse CS, Sorum PC, Sanders KN, Syat BL. Do gender and race affect decisions about pain management?. J Gen Intern Med 2001;16(4):211-17
178. Veldhuijzen DS, Karhof S, Leenders ME, et al. Impact of physicians' sex on treatment choices for low back pain. Pain Pract 2013; 13(6):451-8
179. Aslaksen PM, Flaten MA. The roles of physiological and subjective stress in the effectiveness of a placebo on experimentally induced pain. Psychosom Med 2008;70(7): 811-18
180. Journath G, Hellenius ML, Carlsson AC, et al. Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid
181. US FDA. Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally administered Drug Products -General Considerations. Center for Drug Evaluation and Research (CDER), Rockville, MD, USA; 2003
182. European Medicines Agency. Guideline on the investigation of bioequivalence. EMA; London, UK: 2010
183. Koren G, Nordeng H, MacLeod S. Gender differences in Drug bioequivalence: Time to rethink practices. Clin Pharmacol Ther 2012;93(3):260-2
184. Chen ML, Lee SC, Ng MJ, et al. Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 2000;68(5):510-21
185. Flores Perez J, Juarez Olguin H, Flores Perez C, et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int 2003;20(3):485-94 (Pubitemid 36828481
186. Ashiru DA, Patel R, Basit AW. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm Res 2008; 25(10):2327-33
187. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995;50(1):1-6
188. Soldin OP, Chung SH, Mattison DR. Sex differences in Drug disposition. J Biomed Biotechnol 2011;2011:187103
189. Donovan MD. Sex and racial differences in pharmacological response: Effect of route of administration and drug delivery system on pharmacokinetics. J Womens Health (Larchmt) 2005;14(1):30-7 (Pubitemid 40309364
190. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34(3):203-18 (Pubitemid 28112399
191. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006;5(5):425-38
192. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007;82(1):87-96 (Pubitemid 46944201
193. Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than Do men. Eur J Clin Pharmacol 2008;64(10): 999-1004
194. Pinnow E, Sharma P, Parekh A, et al. Increasing participation of women in early phase clinical trials approved by the FDA. Womens Health Issues 2009;19(2):89-93
195. Yang Y, Carlin AS, Faustino PJ, et al. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002. J Womens Health (Larchmt) 2009;18(3):303-10
196. Rademaker M. Do women have more adverse drug reactions?. Am J Clin Dermatol 2001;2(6):349-51
197. Krahenbuhl-Melcher A, Schlienger R, Lampert M, et al. Drug-related problems in hospitals: A review of the recent literature. Drug Saf 2007;30(5):379-407 (Pubitemid 46740336
198. Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: Analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol 2007;7:9
199. Sikdar KC, Alaghehbandan R, MacDonald D, et al. Adverse drug events in adult patients leading to emergency department visits. Ann Pharmacother 2010; 44(4):641-9
200. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-19 (Pubitemid 38869995
201. Gurwitz JH. The age/gender interface in geriatric pharmacotherapy. J Womens Health (Larchmt) 2005;14(1):68-72 (Pubitemid 40309369
202. Office of Strategic Planning Health Care Financing Administration. The profile of Medicare chart book. U.S. Department of Health and Human Service; 2008
203. Cheng YC, Vyas A, Hymen E, Perlmuter LC. Gender differences in orthostatic hypotension. Am J Med Sci 2011;342(3):221-5
204. Baylis C. Sexual dimorphism of the aging kidney: Role of nitric oxide deficiency. Physiology (Bethesda) 2008;23:142-50
205. Komukai K, Mochizuki S, Yoshimura M. Gender and the renin-Angiotensin- Aldosterone system. Fundam Clin Pharmacol 2010;24(6):687-98
206. Niesters M, Dahan A, Kest B, et al. Do sex differences exist in opioid analgesiä. A systematic review and meta-Analysis of human experimental and clinical studies. Pain 2010;151(1):61-8
207. Kurokawa J, Suzuki T, Furukawa T. New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: Acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci 2009;109(3):334-40
208. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions?. The example of drug-induced long QT syndrome. Drug Saf 2001;24(8):575-85 (Pubitemid 32656071
209. Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: Mechanisms and clinical implications. Am J Med 2010; 123(10):877-84
210. Onder G, Penninx BW, Landi F, et al. Depression and adverse drug reactions among hospitalized older adults. Arch Intern Med 2003;163(3):301-5 (Pubitemid 36183858
211. Zender R, Olshansky E. Women's mental health: Depression and anxiety. Nurs Clin North Am 2009;44(3):355-64
212. Haack S, Seeringer A, Thurmann PA, et al. Sex-specific differences in side effects of psychotropic drugs: Genes or gender?. Pharmacogenomics 2009;10(9):1511-26
213. Regitz-Zagrosek V, Seeland U. Sex and gender differences in clinical medicine. Handb Exp Pharmacol 2012(214):3-22
214. van Kuilenburg AB, Meinsma R, van Gennip AH. Pyrimidine degradation Defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1371-5 (Pubitemid 39625927
215. Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc 2013;16(1): 1-14
216. Abbate R, Mannucci E, Cioni G, et al. Diabetes and sex: From pathophysiology to personalized medicine. Intern Emerg Med 2012;7(Suppl 3):S215-19
217. Rurik I. Nutritional differences between elderly men and women. Primary care evaluation in Hungary. Ann Nutr Metab 2006;50(1):45-50
218. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291(3):335-42 (Pubitemid 38101606
219. Correa-de-Araujo R, McDermott K, Moy E. Gender differences across racial and ethnic groups in the quality of care for diabetes. Womens Health Issues 2006;16(2):56-65
220. de Valk HW, Visser GH. Insulin During pregnancy, labour and delivery. Best Pract Res Clin Obstet Gynaecol 2011;25(1):65-76
221. American Diabetes Association. Insulin administration. Diabetes Care 2003; 26(Suppl 1):S121-4
222. Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract 2005;69(1):14-21 (Pubitemid 40813408
223. Trout KK, Rickels MR, Schutta MH, et al. Menstrual cycle effects on insulin sensitivity in women with type 1 diabetes: A pilot study. Diabetes Technol Ther 2007;9(2): 176-82 (Pubitemid 46652553
224. Gross JL, Kramer CK, Leitao CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: A network meta-Analysis. Ann Intern Med 2011;154(10):672-9
225. Jovanovic L. Sex differences in insulin Dose and postprandial glucose as BMI increases in patients with type 2 diabetes. Diabetes Care 2009;32(12):e148
226. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: A case-control study. Diabetes Care 2008;31(2):199-203 (Pubitemid 351213319
227. National Osteoporosis Foundation. Fast facts on osteoporosis. National Osteoporosis Foundation; Washington, UK: 2005
228. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in Dysglycemia. N Engl J Med 2012;367(4):319-28
229. Gough SC, Belda-Iniesta C, Poole C, et al. Insulin therapy in Diabetes and cancer risk: Current understanding and implications for future study: Proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther 2011; 28(Suppl 5):1-18
230. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients-A nationwide cohort study. PLoS One 2011;6(6):e21368
231. Suissa S, Azoulay L, Dell'Aniello S, et al. Long-Term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011; 54(9):2254-62
232. Morden NE, Liu SK, Smith J, et al. Further exploration of the relationship between insulin glargine and incident cancer: A retrospective cohort study of older Medicare patients. Diabetes Care 2011; 34(9):1965-71
233. Lind M, Fahlén M, Eliasson B, Odén A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 2012;6:53-9
234. Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: The importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol 2013;1(2): 132-9
235. Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: Effect of diabetes duration and treatment. Diabetologia 2014;57(5):927-34
236. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005;28:2543-5 (Pubitemid 41384310
237. Graham TA, McDonald SA, Wright NA. Field cancerization in the GI tract. Future Oncol 2011;7(8):981-93
238. Metformin. Available from: Www.drugs. com/pro/metformin.html
239. Shah J, Fogel J, Balsam L. Importance of creatinine clearance for drug dosing in nursing home residents. Ren Fail 2014; 36(1):46-9
240. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in Diabetics. BMC Cancer 2012;12:410
241. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-Analysis of randomised clinical trials. Diabetologia 2012;55(10):2593-603
242. Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011;7(6):727-36
243. Pollak M. Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 2010;3(9):1060-5
244. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in Diabetic patients treated with metformin: A systematic review and meta-Analysis. PLoS One 2012;7(3):e33411
245. Col NF, Ochs L, Springmann V, et al. Metformin and breast cancer risk: A meta-Analysis and critical literature review. Breast Cancer Res Treat 2012;135(3): 639-46
246. Hardie DG, Hawley SA, Scott JW. AMP-Activated protein kinase-development of the energy sensor concept. J Physiol 2006;574(Pt 1):7-15 (Pubitemid 43905792
247. Zhou J, Huang W, Tao R, et al. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 2009;28(18):1993-2002
248. Memmott RM, Gills JJ, Hollingshead M, et al. Phosphatidylinositol ether lipid analogues induce AMP-Activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. Cancer Res 2008;68(2):580-8 (Pubitemid 351380087
249. Jin Q, Feng L, Behrens C, et al. Implication of AMP-Activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 2007;67(24):11630-9
250. Okoshi R, Ozaki T, Yamamoto H, et al. Activation of AMP-Activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008;283(7):3979-87
251. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67(14):6745-52 (Pubitemid 47105521
252. Jones RG, Plas DR, Kubek S, et al. AMP-Activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18(3):283-93 (Pubitemid 41350534
253. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338(4):265-6 (Pubitemid 28047587
254. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22(6):925-7 (Pubitemid 29241046
255. Orban JC, Giunti C, Levraut J, et al [Metformin-Associated lactic acidosis remains a serious complication of metformin therapy]. Ann Fr Anesth Reanim 2003;22(5):461-5
256. Pertek JP, Vidal S, Mariot J, et al [Metformin-Associated lactic acidosis precipitated by acute renal failure]. Ann Fr Anesth Reanim 2003;22(5):457-60
257. Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract 2000;6(6):442-6
258. Liu F, Lu JX, Tang JL, et al. Relationship of plasma creatinine and lactic acid in type 2 diabetic patients without renal dysfunction. Chin Med J (Engl) 2009; 122(21):2547-53
259. Li Q, Liu F, Tang JL, et al. The gender difference of plasma lactate levels and the influence of metformin in type 2 diabetes patients. Chin J Endocrinol Metab 2010;26: 372-6
260. Li Q, Liu F, Zheng TS, et al. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin 2010;31(2):184-90
261. Baraona E, Abittan CS, Dohmen K, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001;25(4): 502-7 (Pubitemid 32323416
262. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990;322(2): 95-9 (Pubitemid 20023867
263. Karim A, Zhao Z, Slater M, et al. Replicate study design in bioequivalency assessment, pros and cons: Bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation. J Clin Pharmacol 2007;47(7):806-16
264. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8 (Pubitemid 44106500
265. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same?. A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23(6):479-84 (Pubitemid 47520905
266. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-Analysis. Oncologist 2012;17(6):813-22
267. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343(16):1134-8
268. Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARG gene variant on obesity characteristics in Brazil. Braz J Med Biol Res 2007;40(7):927-32 (Pubitemid 47232877
269. Ben Ali S, Ben Yahia F, Sediri Y, et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-Activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem 2009; 42(16-17):1642-7
270. Dedoussis GV, Vidra N, Butler J, et al. Peroxisome proliferator-Activated receptorgamma (PPARgamma) Pro12Ala polymorphism and risk for pediatric obesity. Clin Chem Lab Med 2009;47(9):1047-50
271. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43 (Pubitemid 44903747
272. Kahn SE, Haffner SM, Viberti G, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: Observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2010;33(1):177-83
273. Aubert RE, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010; 12(8):716-21
274. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007;30(9):RC26-30
275. Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: Evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010; 95(10):4560-5
276. Wang X, Kilgore MW. Signal cross-Talk between estrogen receptor alpha and beta and the peroxisome proliferator-Activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol 2002;194(1-2):123-33 (Pubitemid 35291927
277. Foryst-Ludwig A, Clemenz M, Hohmann S, et al. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-Talk with PPARgamma. PLoS Genet 2008;4(6):e1000108
278. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916-22
279. Bazelier MT, de Vries F, Vestergaard P, et al. Use of thiazolidinediones and risk of bladder cancer: Disease or drugs?. Curr Drug Saf 2013;8(5):364-70
280. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007;16(5): 485-92 (Pubitemid 46824269
281. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25(12):1476-81 (Pubitemid 46733074
282. Anichini R, Cosimi S, Di Carlo A, et al. Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: A real world experience. Diabetes Metab Syndr Obes 2013;6:123-9
283. Guedes EP, Hohl A, de Melo TG, Lauand F. Linagliptin: Farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr 2013;5(1):25
284. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16(1):e165-70
285. Halimi S, Raccah D, Schweizer A, Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin 2010;26(7):1647-56
286. Ahren B, Sorhede Winzell M, Burkey B, Hughes TE. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-Term augmentation of insulin secretion in mice. Eur J Pharmacol 2005;521(1-3):164-8 (Pubitemid 41427804
287. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7 (Pubitemid 34680970
288. West DS, Elaine Prewitt T, Bursac Z, Felix HC. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring) 2008;16(6):1413-20 (Pubitemid 351770519
289. Anderwald C, Gastaldelli A, Tura A, et al. Mechanism and effects of glucose absorption During an oral glucose tolerance test among females and males. J Clin Endocrinol Metab 2011;96(2):515-24
290. Franconi F, Carru C, Malorni W, et al. The effect of gender on cardiovascular pharmacology. Curr Pharm Design 2011; 17(11):1095-107
291. Gulbins H, Vogel B, Reichenspurner H. Gender effects on health care costs in cardiovascular medicine-A black box?. Thorac Cardiovasc Surg 2013;61(1):74-8
292. Sasser AC, Taylor M, Birnbaum HG, et al. Assessing the economic impact of chronic conditions in postmenopausal women. Expert Opin Pharmacother 2005;6(11): 1803-14 (Pubitemid 41358419
293. Owens GM. Gender differences in health care expenditures, resource utilization, and quality of care. J Manag Care Pharm 2008; 14(3 Suppl):2-6
294. Semark B, Engstrom S, Brudin L, et al. Factors influencing the prescription of drugs of different price levels. Pharmacoepidemiol Drug Saf 2013;22(3):286-93
295. Jackson PB, Williams DR. The intersection of race, gender, and SES: Health paradoxes. In: Schulz AJ, Mullings L, editors. Gender, race, class, and health: Intersectional approaches. Jossey-Bass; San Francisco, CA, USA: 2006. p. 131-62
296. Davis K. Intersectionality as buzzword. A sociology of science perspective on what makes a feminist theory successful. Fem Theory 2008;9:67-85